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Abstract
IL-12 and IL-23 cytokines respectively drive Th1 and Th17 type responses. Yet, little is known regarding the biology of these
receptors. As the IL-12 and IL-23 receptors share a common subunit, it has been assumed that these receptors are co-
expressed. Surprisingly, we find that the expression of each of these receptors is restricted to specific cell types, in both
mouse and human. Indeed, although IL-12Rb2 is expressed by NK cells and a subset of cd T cells, the expression of IL-23R is
restricted to specific T cell subsets, a small number of B cells and innate lymphoid cells. By exploiting an IL-12- and IL-23-
dependent mouse model of innate inflammation, we demonstrate an intricate interplay between IL-12Rb2 NK cells and IL-
23R innate lymphoid cells with respectively dominant roles in the regulation of systemic versus local inflammatory
responses. Together, these findings support an unforeseen lineage-specific dichotomy in the in vivo role of both the IL-12
and IL-23 pathways in pathological inflammatory states, which may allow more accurate dissection of the roles of these
receptors in chronic inflammatory diseases in humans.
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Introduction
The heterodimeric receptors for both IL-12 and IL-23 share a
common protein subunit, namely IL-12Rb1, and are thus often
depicted at the same cell membrane [1–5]. IL-12Rb2 and IL-23R,
the respective specific subunits of IL-12 and IL-23 receptors, show
high homology and likely arose by gene duplication [1]. This
suggests a possible coordination for the expression of both IL-12
and IL-23 receptors [1]. Yet, the expression pattern of the
receptors for IL-12 and IL-23 has not been defined.
A better comprehension of the biology of the receptors for IL-12
and IL-23 is essential, as both pathways are involved in chronic
inflammatory diseases [6–9]. IL23R was first discovered to have a
role in human disease as a result of one of the first published GWA
studies of a complex trait. Specifically, it was demonstrated that
the Glu allele at residue 381 in the IL-23R protein conferred
significant protection against developing Crohn’s disease and
ulcerative colitis, while other genetic variants in this gene, in
contrast, conferred increased risk [6]. Recent targeted deep re-
sequencing experiments in Crohn’s disease patients and healthy
controls have identified further protective variants in the IL23R
[10,11]. In an association study of psoriasis, it was shown that the
381Glu allele had a similar protective effect, consistent with the
clinical observations that psoriasis and Crohn’s disease are co-
segregated with high frequency [12]. Further supporting a central
role of this pathway in chronic inflammatory disease susceptibility
are the confirmed associations of the IL12B gene (encoding the
p40 subunit of both IL-12 and IL-23 cytokines) with Crohn’s
disease, ulcerative colitis and psoriasis; the JAK2 gene (a proximal
kinase in the IL-23R pathway) in Crohn’s disease; and the STAT3
gene (immediately downstream of JAK2) in Crohn’s disease and
ulcerative colitis [13,14]. Similarly, genetic polymorphisms in
IL12RB2 are also associated with increased risk of chronic
inflammatory disease. Notably, a recent GWA study of primary
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biliary cirrhosis revealed an association with IL12RB2, IL12A (a
gene encoding for the p35 subunit of the IL-12 cytokines) and
STAT4 (downstream of IL12RB2) [9,15]. Genetic polymorphisms
in both the IL-12 and IL-23 pathways are thus strongly associated
with susceptibility to inflammatory diseases. Moreover, these
pathways are current molecular targets in the treatment of chronic
inflammatory diseases. It is thus imperative that we understand the
cellular players of the IL-12 and IL-23 pathways and their role in
inflammation.
In this study, we demonstrate that, although they share a
common subunit, IL-23 and IL-12 receptors are not expressed on
the same cell populations. We establish that there is a strong
dichotomy between IL-12 and IL-23 receptor expressing cells,
which is quite conserved in humans and mice. We additionally
exploit an IL-12 and IL-23 dependent model to demonstrate that
there is an intricate interplay between the IL-12 and IL-23
pathways in regulating both systemic and local innate inflamma-
tory responses.
Materials and Methods
Ethics Statement
The work with human samples was approved by the Montreal
Heart Institute Research Ethics Board (#12–1363). Peripheral
blood was obtained from healthy volunteers after obtaining written
informed consent. The mouse studies were approved by the
Figure 1. IL23R and IL12RB2 are not transcribed within the same lymphocyte populations. The relative mRNA transcription level of IL23R,
IL12RB1 and IL12RB2 in (A) different sorted PBMC populations of healthy donors and in (B) murine sorted spleen cell populations is shown. (C) The
relative mRNA transcription level of Il23r, Il12rb1 and Il12rb2 in sorted CD27+/2 cd T cell populations from mouse spleens is shown. For all panels, the
horizontal bar represents the mean of each group and each symbol represents one sample.*, p,0.05, **p,0.01.
doi:10.1371/journal.pone.0089092.g001
IL-12Rb2 and IL-23R Dichotomy
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Figure 2. Il23r expressing cells exhibit a mixed Th1/Th17 signature profile. (A) The relative mRNA transcription level of Rorc, Il17a, Il22,
Tbx21, and Ifng in sorted murine spleen cells is shown. (B) The relative mRNA transcription level of Il23r, Il12rb1, Il12rb2, Rorc, Il17a, Tbx21 and Ifng in cd
IL-12Rb2 and IL-23R Dichotomy
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Maisonneuve-Rosemont Hospital ethics committee and overseen
by the Canadian Council for Animal Protection.
PBMCs
PBMCs were obtained by centrifugation of collected blood in
BD VacutainerH CPT Cell Preparation Tube with Sodium
Citrate, and washed with DPBS for platelet removal. CD14+
monocytes were enriched from PBMCs with CD14 MicroBeads
(MACS Miltenyi Biotec) on LS columns. Both CD14- and CD14+
fractions were treated with FcR blocking reagent (MACS Miltenyi
Biotec) and further stained for cell sorting.
Mice
Eight- to 12 week-old mice were used for all the experiments.
C57BL/6J mice (#664), IL-12Rb22/2 (#3248), RORct2/2
(#7572) and Rag12/2 (#2216) on C57BL/6 background were
purchased from the Jackson Laboratory. IL-12Rb22/2, IL-23R-
eGFP+/2 and IL-23R-eGFP homozygous mice [16] (referred to in
the text as IL-23R2/2) were maintained on a C57BL/6
background. IL-23R2/2 and IL-12Rb22/2 were bred to
Rag12/2 to respectively generate IL-23R2/2.Rag12/2 and IL-
12Rb22/2.Rag12/2 mice. All mice were maintained at the
Maisonneuve-Rosemont Hospital housing facility (Montreal,
Canada).
Mouse Cell Isolation
Spleens, lymph nodes, and thymus were treated with collage-
nase (1 mg/ml; type V from Clostridium histolyticum; Sigma-
Aldrich) for 15 min at 37uC. Bone marrow was flushed from the
femur and tibias. Lungs were perfused with PBS, harvested, and
digested for 30 min at 37uC with 1 ml collagenase. Intestines were
collected in cold media and kept on ice prior to treatment. They
were then placed on a shaker at 450 rpm for 20 minutes at 37uC
in RPMI medium containing 30% FBS, 5 mM EDTA and
145 mg/mL DTT. Following this incubation, the intestines were
hand-shaken in RPMI containing 2 mM EDTA and filtered
through a kitchen strainer. Intestines were then cut in 1 cm
fragments and placed in a shaker at 450 rpm for 30 minutes at
37uC with RPMI containing 50 mg/mL liberase, 14.5 mg/mL
DNase I and 135 mg/mL collagenase V. After digestion, cell
suspensions of the lamina propria are obtained by pressing the
tissue fragments through a 100 mm sterile cell strainer (BD
BioSciences, Mississauga, Canada). All organs were finally passed
through a 70-mm cell strainer (BD Biosciences, Mississauga,
Canada) to yield single-cell suspensions prior to staining with
antibodies. NH4Cl was used for erythrocyte lysis of single cell
suspensions on the spleen, bone marrow and lung. Cell counts
were performed by trypan blue exclusion using a hemacytometer.
Three million cells were stained with different combinations of
fluorochrome-conjugated antibodies.
Flow Cytometry
Human CD14- PBMC fraction was stained with antibodies to
the following markers: CD3 APC-Cy7 (clone UCHT1), CD4
FITC (clone RPA-T4), CD8a APC (clone RPA-T8), TCR cd
biotin (clone B1), streptavidin PE-Cy5 and CD19 PE (clone
HIB19) from Biolegend; CD56 PE-Cy7 (clone B159) from BD
Biosciences. Human CD14+ monocyte-enriched fraction was
counterstained with goat anti-mouse IgG2a FITC (AbD Serotec)
to bind bead-coupled monoclonal anti-human CD14 (mouse
IgG2a). Cell sorting was performed on a FACS Aria III (BD
Biosciences). Electronic gating was performed on CD14- PBMC
fraction to sort B cells (CD3- CD19+), CD4 T cells (CD3+ CD4+),
CD8 T cells (CD3+ CD8+), cd T cells (CD3+ TCR cd+) and NK
cells (CD3- CD19- CD56+), and on CD14+ monocyte-enriched
fraction to sort monocytes (FSC/SSC gating and IgG2a+). Cell
sorting was performed on a FACS Aria III (BD Biosciences).
Murine cells were stained with antibodies to the following
markers: CD3e PE and APC (clone 145.2C11), CD8a PE (clone
53-6.7), CD11b Pacific Blue (clone M1/70), CD11c PE and PE-
Cy7 (clone N418), CD19 PerCP (clone 6D5), CD27 PE (clone
LG.3A10), CD45 PE-Cy7 (clone 30-F11), B220 (CD45R)
Alexa700 (clone RA3-6B2), CD49b Pacific Blue (clone DX5),
CD90.2 PerCP (clone 30-H12), CD117 APC (clone 2B8), CD127
Biotin (clone A7R340), TCRcd PerCP-Cy5.5 (clone GL3), TCRb
Alexa700 (clone H57-597), NK1.1 APC (clone PK136), Gr1
PerCP (clone RB6-8C5), from Biolegend; Sca1 PE-Cy7 (clone
D7), IL12Rb2 (clone HAM10B9), anti-hamster IgG PE (clones
G70-204, G94-90.5) from BD Biosciences; Streptavidin Alexa700
from Invitrogen; NKp46 PE (clone 29A1.4), CD4 PE-Cy7 (clone
GK1.5) from eBioscience; and mouse pDC antigen-1 APC (clone
JF05-1C2) from Miltenyi Biotec; IL12Rb2 APC, PE (clone
305719) from R&D Systems. Cell viability was assessed using
Viability dye eFluor 780 from eBioscience. For analyzing IL23R-
eGFP positive cells, flow cytometry data collection was performed
on an LSRII (BD). Files were analyzed using FlowJo software
(TreeStar, Inc). Doublet cell exclusion was performed by
electronic gating based on FSC and SSC profiles. Cell sorting
was performed on a FACS Aria III (BD Biosciences). Electronic
gating was performed to sort B cells (CD19+ B220+), CD4 T cells
(TCRb+ CD4+), CD8 T cells (TCRb+ CD4+), cd T cells (TCR
cd+) and NK cells (CD49b+ B220-). For specific populations of cd
T cells, electronic gating was performed to sort CD27+ and CD27-
TCR cd+ cells.
RNA Isolation, cDNA Preparation, and RT-PCR
mRNA from sorted human PBMC or mouse spleen cells was
extracted using RNeasy Mini Plus or Micro Plus kits, respectively
for more or less than 500 000 cells, according to the manufac-
turer’s instructions. Human mRNA was treated with DNaseI
according to manufacturer instructions. After storage at 4uC in
RNAlater (Qiagen), mRNA from proximal colon was isolated by
using mechanical homogenization with Tissue Lyser (Qiagen)
followed by extraction with RNeasy Mini Plus kit according to the
manufacturer’s instructions. Total RNA was quantified on RNA
6000 Nano chips on a 2100 Bioanalyzer (Agilent Technologies) or
on Tecan’s NanoQuant Plate on Infinite Reader. cDNA was
generated using High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems). RT-PCR was performed on cDNA using
SYBR green chemistry (Applied Biosystems) and reactions were
run on an RT-PCR system (ABI7500; Applied Biosystems or
Mx3005P; Agilent Technologies). For murine mRNA quantifica-
tions, the following primers were used: Gapdh primers 59-
CCCACTTGAAGGGTGGAGCCAA-39 and 59-TGGCATG-
GACTGTGGTCATGA-39; Il23r primers 59-
GCTCGGATTTGGTATAAAGG-39 and 59-ACTTGGTATC-
TATGTAGGTAGG-39; Il12rb1 primers 59-ACTG-
T cells from RORct2/2 mice is shown. (C) The relative mRNA transcription level of Il23r, Il12rb1, Il12rb2, Rorc, Il17a, Il22, Tbx21 and Ifng in IL23R-eGFP
sorted spleen cells and NK cells is shown. For all panels, the horizontal bar represents the mean of each group and each symbol represents one
sample.*, p,0.05 compared to each group.
doi:10.1371/journal.pone.0089092.g002
IL-12Rb2 and IL-23R Dichotomy
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GAATGTGTCTGAAG-39 and 59-CGTATCTG-
GATCTCTTGG-39; Il12rb2 primers 59-CCTCAATGGTATAG-
CAGAAC-39 and 59-TAGCCTTGGAATCCTTGG-39; Rorc
primers 5,-AGTCGTCCTAGTCAGAATG-39 and 59-
ATGTTCCACTCTCCTCTTC-39; Il17a primers 59-AGGCAG-
CAGCGATCATCC-39 and 59-GTGGAACGGTTGAGG-
TAGTC-39; Il22 primers 59-CAACTTCCAGCAGCCATAC-39
and 59-ATCCTTAGCACTGACTCCTC-39; Tbx21 primers 59-
GTTCAACCAGCACCAGAC-39 and 59-TCCACCAAGACCA-
CATCC-39; Ifng primers 59-CTGAGACAATGAACGCTACAC-
39 and 59-TCCACATCTATGCCACTTGAG-39; Il6 primers 59-
CAAGAGACTTCCATCCAG-39 and 59-GCAT-
CATCGTTGTTCATAC-39; Ccl2 primers 59-AATGAGATCA-
GAACCTACAAC-39 and 59-TCCTACAGAAGTGCTTGAG-
39; Tnf primers 59-TTCTCATTCCTGTTGTGG-39 and 59-
ACTTGGTGGTTTGCTACG-39; Il1b primers 59-GAATCTA-
TACCTGTCCTGTG-39 and 59-GTGAAGTCAAT-
TATGTCCTG-39; Il10 primers 59-CTAACCGACTCCT-
TAATGC-39 and 59-AATCACTCTTCACCTGCTC-39; Il12a
primers 59-CCAGGTGTCTTAGCCAGTC-39 and
59CTCGTTCTTGTGTAGTTCCAG-39;, Il12b primers 59-
GAATGGCGTCTCTGTCTG-39 and 59-
GCTGGTGCTGTAGTTCTC-39;, Il23 primers 59-
CTGCTTGACTCTGACATC-39 and 59-CACTGCTGACTA-
GAACTC-39;, Il18 primers 59-CAAATGGCCAGTGAACCC-39
and 59-AACTCCATCTTGTTGTGTCC-39. For human mRNA
quantification, the following primers were used: HPRT primers 59-
TGGCGTCGTGATTAGTGATG-39 and 59-CAGAGGGCTA-
CAATGTGATGG-39; IL23R primers 59- GCCAAGCAGCAAT-
TAAGAAC-39 and 59- GACACAGGT TACTTCATCAGG-39;
IL12RB1 primers 59- CACAGAGACCCAAGTTAC C-39 and 59-
GAGGCG AAGAAGATGAGC-39; IL12RB2 primers 59-
GTTGGAGTGATTGGAGTG-39 and 59-
CCTGTGATGTTCTGTGTC-39. The comparative threshold
cycle method and an internal control (Gapdh or HPRT) were used
for normalization of the target genes.
Induction of Colitis
For colitis experiments, IL-12Rb22/2.Rag12/2 IL-23R+/
2.Rag12/2 and IL-23R2/2.Rag12/2 mice were injected intra-
peritoneally with anti-CD40 IgG2a monoclonal antibody, clone
FGK45 (BioXCell, West Lebanon, NH) diluted in PBS [17].
200 mg of anti-CD40 antibody was injected for 20 g of mouse
weight. After antibody injection, mice were monitored daily and
sacrificed after 7 days or when they were moribund or had lost
more than 25% of their initial weight. Serum, liver, lung, heart
and intestines were collected at day 7. In some experiments,
intestines were collected at day 2. Mice were matched for age,
weight and sex in all groups.
Serum Cytokines
The Cytometric Bead Array Flex Set (BD Biosciences) was used
to simultaneously detect IFN-c, IL-1b, IL-6, IL-12p70, TNF-a,
CCL2, and CXCL1 whereas the FlowCytomix (eBioscience) was
used to quantify IL-18 and IL-23p19 serum levels according to the
respective manufacturers’ instructions and analyzed with a FACS
Canto and BD LSRII (BD Bioscience). Standard curves were
generated by using reference concentrations supplied by the
manufacturers.
Histopathology Studies
For histopathological examination, samples of the liver, lung,
heart and colon were fixed in 10% buffered formalin. After
paraffin embedding, 5-mm-wide tissue sections were stained with
hematoxylin-eosin according to standard protocol and examined
by light microscopy. Criteria for colitis included inflammatory
infiltrate of the lamina propria, glandular epithelial hyperplasia
and goblet cell depletion. All samples were examined in a blinded
fashion.
Statistics
The data below the detection limit of the assays were given the
arbitrary value of zero to allow for statistical analyses. Data were
tested for significance using the non-parametric, two-tailed Mann-
Whitney U test with a minimal threshold of 0.05, in the SPSS 19.0
software.
Results
IL23R and IL12RB2 are not Transcribed within the Same
Lymphocyte Populations
As both IL-12 and IL-23 receptors share a common subunit,
namely IL-12Rb1, it has been implied that these receptors are co-
expressed. Yet, the pattern of expression of IL-23 and IL-12
receptors is poorly defined. To characterize the expression of these
two receptors in different cell populations, we sorted various
lymphocytic subsets in PBMC from healthy donors and quantified
the level of IL23R, IL12RB1 and IL12RB2 mRNA. Transcripts for
IL12RB1 were found in all sorted PBMC populations, with lowest
levels in B cells and monocytes and highest levels in NK cells
(Figure 1A). In contrast, IL23R mRNA expression was limited to T
cell subsets, with highest expression in both CD8 and cd T cells,
while IL12RB2 mRNA was expressed in both cd T cells and NK
cells (Figure 1A). The fact that IL12RB2 mRNA is most abundant
in NK cells is consistent with the original name for IL-12, namely
natural killer cell stimulatory factor [18,19]. Most notably, the
receptors for IL-12 and IL-23 only appeared to be co-expressed in
cd T cells.
To further explore this unexpected pattern of expression for IL-
12 and IL-23 receptors, we opted to examine the mRNA levels of
Il23r, Il12rb1 and Il12rb2 in mouse spleen cells. As for human
PBMCs, the mouse spleen presents with a heterogeneous
lymphocyte population and is the secondary lymphoid organ best
representing cellular populations found in the blood. The mRNA
profiles of Il23r, Il12rb1 and Il12rb2 show a similar transcription
pattern to that of human PBMCs in lymphoid cell subsets isolated
from mouse spleens. Namely, Il23r mRNA is most abundant in cd
T cells and Il12rb2 is primarily expressed in NK cells, and Il12rb2
mRNA is also detected at low levels in cd T cells (Figure 1B).
Thus, the patterns of expression of IL-12Rb1, IL-12Rb2 and IL-
23R are relatively conserved between lymphocytes from human
blood and mouse spleen, where only cd T cells present with
detectable levels of all three transcripts coding for the three
proteins that constitute the IL-12 and IL-23 receptors.
Recently, CD27 was shown to efficiently segregate both IL-17-
and IFN-c-producing cd T cell subsets [20]. As the IL-17 and
IFN-c response are respectively associated with IL-23 and IL-12
pathways, we postulated that the CD27+ and CD27- cd T cells
may exhibit distinct expression patterns of IL-12 and IL-23
Figure 3. IL-23R is not limited to T cells. (A) Extracellular staining of spleen cells in IL23R-eGFP+/2 mice, gated on eGFP positive cells. (B)
Extracellular staining of spleen in IL23R+/2.Rag12/2 mice, gated on eGFP positive cells. (C) Pie chart representation of subpopulations within the
IL23R-eGFP positive cells, in the IL-23R-eGFP+/2 mice and IL-23R-eGFP+/2.Rag12/2 mice. n = 3.
doi:10.1371/journal.pone.0089092.g003
IL-12Rb2 and IL-23R Dichotomy
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receptors, respectively. Indeed, the CD27+ cd T cells express
Il12rb2 mRNA with no detectable expression of Il23r (Figure 1C).
Conversely, Il23r, but not Il12rb2, mRNA was detected in the
CD27- cd T cell subset (Figure 1C). To determine whether this
dichotomous expression of Il12rb2 and Il23r reflects Th1 and
Th17 signature profiles, we quantified both Th1 and Th17
signature genes in lymphoid subsets. We found that total cd T cells
expressed Rorc and Il17a mRNA, associated with the Th17
signature and in line with a predominant expression of Il23r
mRNA in this subset (Figure 2A). In addition, total cd T cells did
not express Tbx21 nor Ifng mRNA, which were instead found to be
expressed at high levels in NK cells, in agreement with IL-12Rb2
expression being associated with a Th1 signature (Figure 2A).
Interestingly, Rorc, which encodes for the RORct transcription
factor, has been recently suggested to precede Il23r mRNA
expression, at least in Th17 cells [21]. Hence, we speculated that
the IL-17 producing IL23R+ cd T cell subset would be Rorc-
dependent. Indeed, cd T cells from RORct2/2 mice specifically
expressed Il12rb2 mRNA and not ll23r (Figure 2B). Moreover,
they specifically express the Th1 signature genes, namely Tbx21
and Ifng mRNA (Figure 2B).Taken together, these results favor a
model where the receptors for IL-12 and IL-23 are not co-
expressed within a given lymphocyte subset and that the
expression of these different receptors are driven by different
transcription factors.
IL23R is Not Limited to T Cells
In mice, Il23r mRNA expression was only detected in CD27- cd
T cells among the immune cell types tested, whereas in humans
both CD8 T cells and cd T cells carried quantifiable levels of
IL23R mRNA (Figure 1). To more precisely define the immune
cell types expressing the IL-23R, we took advantage of the IL23R-
eGFP reporter mouse [16], wherein we sorted all eGFP+ cells
from the spleen. Unfortunately, there are currently no reporter
mice for Il12rb2 available. In addition, none of the commercially
available antibodies to IL-12Rb2 provided specific staining. In
fact, two distinct antibody clones, namely 305719 from R&D
Systems and HAM10B9 from BD Bioscience, non-specifically
stained spleen cells from IL12Rb22/2 mice and did not label NK
cells in IL12Rb2 sufficient mice, precluding a more exhaustive
characterization of IL-12Rb2 expression (Figure S1). We thus
opted to compare IL23R-eGFP+ sorted spleen cells with total NK
cells, where NK cells serve as a representative cell population
bearing high levels of both Il12rb1 and Il12rb2 mRNA transcripts
and undetectable levels of Il23r mRNA transcripts (Figure 1).
Expectedly, sorted IL23R-eGFP+ cells express Il23r and Il12rb1,
but not Il12rb2 mRNA (Figure 2C). As for sorted cd T cells
(Figure 2A), IL23R-eGFP+ cells also express Rorc and Il17a
mRNA (Figure 2C). Surprisingly, however, Il22, Tbx21 and Ifng
mRNA were detected in IL23R-eGFP+ cells (Figure 2C), but not
in cd T cells (Figure 2A), suggesting that IL23R-eGFP+ cells from
the mouse spleen are not exclusively cd T cells.
Figure 4. IL-23R+ cells in the intestine are mostly innate lymphoid cells. (A) The percentage and the absolute number of IL-23R-eGFP+ cells
in lymphoid organs is depicted. The horizontal bar represents the mean of each group. Each symbol represents data from one mouse. (B) The
extracellular staining strategy for the identification of specific immune cellular subsets from total cells in the lamina propria of the small intestine and
colon is shown. Electronic gating of viable hematopoietic cells was achieved by using the viable exclusion dye and CD45 expression. cd T cells (CD3e+
TCR cd+), NK cells (CD49b+), B cells (CD19+) and innate lymphoid cells (CD117+CD90+). (C) Identification of IL-23R-eGFP+ immune cell subsets from
IL-23R-eGFP+/2 mice based on the strategy defined in B. (D) Flow cytometry profiles of IL-23R-eGFP expression in CD11c and CD11b expressing cells.
n = 2.
doi:10.1371/journal.pone.0089092.g004
Figure 5. Anti-CD40 injection in Rag-deficient mice leads to multi-organ inflammatory cellular infiltration. Representative H&E
microphotographs of liver, lung, heart and colon from C57BL6.Rag12/2mice are shown. At day 0, mice received 200 ml of saline solution (control, top
panels) or 200 mg of anti-CD40 (bottom panels) by intraperitoneal route. Neither inflammatory nor structural changes are observed in the tissues of
mice that received the saline solution. The liver, lung and heart of mice treated with anti-CD40 show inflammatory cellular infiltrations (asterisk) near
blood vessels (arrows). The colon of anti-CD40 treated mice presents with a mild inflammatory response at the mucosa, a decrease in goblet cells as
well as gland arborization.
doi:10.1371/journal.pone.0089092.g005
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Figure 6. IL-12Rb2+ and IL-23R+ innate immune cells both contribute to the systemic inflammatory response. C57BL/6.Rag12/2, IL-
23R2/2.Rag12/2, and IL-12Rb22/2.Rag12/2mice were injected with anti-CD40 antibody or PBS (6 to 11 mice per group). (A) Mouse weight relative to
the initial weight is shown. a, b p,0.05. (B) Day 7 serum concentrations of IFN-c, IL-1b, IL-6, IL-12p70, IL-18, IL-23p19, TNF-a, CCL-2 and CXCL1 were
quantified. Each symbol represents data for one mouse. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0089092.g006
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Figure 7. IL-23R+ innate lymphocytes play a dominant role in the intestinal inflammatory response. (A) Histological examination of the
colon. Increase in the thickness of the mucosa, inflammatory infiltration (indicated by arrows), goblet cell depletion, discrete glandular hyperplasia
and edema of the submucosa were found in C57BL/6.Rag12/2 and IL-12Rb22/2.Rag12/2 mice which received anti-CD40 antibody. Original
magnification 100X. Scale = 100 mm. (B) The relative mRNA transcription levels of cytokines and chemokines in the proximal colon are shown. Each
symbol represents data for one mouse. *p,0.05. **p,0.01. ***p,0.001.
doi:10.1371/journal.pone.0089092.g007
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To characterize these unidentified IL23R+ cells, we performed
an exhaustive characterization of IL23R-eGFP+ cells by flow
cytometry. In the spleen, IL23R-eGFP+ cells compose less than
0.2% of total cells (Figure S2A). In agreement with the Il23r
mRNA profiles (Figure 1B), a large proportion of IL23R-eGFP+
cells are cd T cells, such that they compose approximately 35–
40% of all IL23R-eGFP+ cells (Figure 3A). Interestingly, the eGFP
signal from the IL23R-eGFP transgene was also detected in a
small proportion of both CD4 and CD8 T cells (Figure 3A),
though the mRNA level of Il23r was undetectable within total
CD4 and CD8 T cells (Figure 1B). This is likely due to the fact that
fewer than 0,1% of total CD4 or CD8 T cells express IL-23R,
while the IL-23R is expressed by more than 7% of total cd T cells
(Figure S2D). This result highlights the enhanced sensitivity of the
IL23R-eGFP model for precisely defining the expression pattern
of IL-23R. Importantly, regardless of this enhanced sensitivity, NK
cells do not express IL-23R, as no IL23R-eGFP+ cells express
CD49b, the pan-NK cell marker (Figure S2B).
In addition to cd T cells as well as CD4 and CD8 ab T cells, a
substantial percentage of IL23R-eGPF+ cells were positive for
CD3, although they lacked the expression of CD4, CD8 and cd
TCR (Figure 3A). This phenotype is consistent with the
description of both DN T cells and NKT cells, two cell types
responding to IL-23 [22,23]. A small pool of B cells was also found
to express IL23R-eGFP (Figure 3A), in agreement with a role for
IL-23 in human tonsilar B cell response [24]. The remaining IL-
23R expressing cells exhibited the phenotype of innate lymphoid
cells, namely CD3- CD127+ CD117+ Lti-like cells and NKp46+
CD127+ CD117+ CD49b- cells (NCR+ ILC3 cells) (Figure 3A)
[25]. As innate lymphoid cells compose only a small proportion of
total spleen cells, we opted to confirm the expression of IL-23R in
these cell subsets by taking advantage of Rag12/2 mice, which
lack both B and T cells. In the spleen of Rag12/2 mice, more than
95% of IL23R-eGFP+ were Lti-like cells and NCR+ ILC3 cells
(Figure 3B). NK cells, macrophages, monocytes or granulocytes,
did not express IL-23R (Figure S2B, C). However, and unexpect-
edly, IL-23R was also not expressed on dendritic cells, although
IL-23R expression on dendritic cells had been previously reported
using an IL-23-Fc fusion protein [26] (Figure S2B, C). Together,
these results define IL-23R expressing cells as T cells (mainly cd T
cells), innate lymphoid cells as well as some B cells (Figure 3C).
Notably, although Lti-like and ILC3 have mostly been reported in
the lymph nodes and mucosal tissues respectively, we find a
discrete population of IL-23R+ innate lymphoid cells in the spleen,
suggesting that these cells may also contribute to systemic immune
responses.
This observation prompted us to examine the distribution of IL-
23R+ cells in other lymphoid organs. We found a sizeable
proportion and absolute number of IL-23R+ cells in all lymphoid
organs examined, where the gut-associated lymphoid tissue
exhibited the highest number of IL-23R+ cells (Figure 4A). As
the cellular distribution of immune cell types differs considerably
between the spleen and the lamina propria of the intestine, we
determined the composition of the IL-23R+ cells within this latter
tissue. As for the spleen, we found that the IL-23R-eGFP+ cells in
the lamina propria of both the small intestine and the colon are
comprised of T cells, innate lymphoid cells and B cells (Figure 4B–
C). The T cells were mostly cd T cells and these IL-23R-eGFP+
cd T cells lacked CD27 expression (Figure S3). However, in
contrast with the spleen, the predominant IL-23R+ cell subset in
the lamina propria of the gut are innate lymphoid cells (Figure 4B–
C). As for the spleen, IL-23R expression was not detected on
CD49b+ NK cells. Moreover, neither CD11c+ dendritic cells nor
CD11b+ macrophages expressed IL-23R in the lamina of the
Figure 8. The anti-CD40-induced inflammatory response does
not alter the distribution of immune cells in the gut-associated
lymphoid tissue. IL-23R-eGFP2/2.Rag12/2 mice were treated with
anti-CD40 and the intestines were processed at day 2. (A) The
extracellular staining strategy for the identification of innate lymphoid
cells (CD117+ CD90+) and NK cells (CD49b) within total cells in the
lamina propria of the small intestine and colon. Electronic gating of
viable hematopoietic cells was achieved by using the viable exclusion
dye and CD45 expression. (B) Identification of IL-23R-eGFP+ immune
cell subsets from IL-23R-eGFP2/2.Rag12/2 anti-CD40-treated mice
based on the strategy defined in A. (C) Flow cytometry profiles of IL-
23R-eGFP expression in CD11c and CD11b expressing cells. n = 2.
doi:10.1371/journal.pone.0089092.g008
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small intestine and colon (Figure 4D). Together, these results
suggest that the distribution of IL-23R+ cells is similar between the
spleen and intestinal lymphoid tissue.
Integration of IL-12Rb2 and IL-23R Pathways in Systemic
Inflammatory Responses
The role of the IL-12 and IL-23 pathways has been highlighted
in various inflammatory settings, including chronic inflammatory
diseases and cancers [27]. As we have defined that IL12Rb2 and
IL23R are expressed by distinct immune cell types (Figure 1–4),
we aimed to revisit the unique role of these receptors in an IL-12
and IL-23-dependent inflammatory response. Administration of
anti-CD40 antibody in Rag2/2 mice provides a model of
inflammation dependent on both IL-12 and IL-23 cytokines,
and leads to a systemic inflammatory response characterized by
the increased levels of various cytokines in the serum [17]. In
addition, this anti-CD40-induced systemic inflammatory response
leads to cellular infiltration in various tissues, namely the liver,
lung, heart and colon (Figure 5). In the Rag2/2 setting, only
innate lymphoid cells express the IL-23 receptor (Figure 3B),
whereas the IL-12 receptor is expressed by NK cells (Figure 1B)
reflecting the dichotomous expression profile of these receptors in
distinct cell types. We thus generated IL-23R2/2.Rag12/2 and
IL-12Rb22/2.Rag12/2 mice, to specifically investigate the
contribution of each receptor and their corresponding cell type
in the inflammatory response. Intraperitoneal injection of anti-
CD40 induces a rapid and significant weight loss in all strains of
mice (Figure 6A). This rapid weight loss is indicative of the severity
of the systemic inflammatory response, where mice expressing
both IL-23 and IL-12 receptors present with the most severe
weight loss, while those lacking either the Il23r or the Il12rb2
subunits show only a transient weight loss. Still, IL-23R2/
2.Rag12/2 mice exhibit a more severe weight loss than IL-
12Rb22/2.Rag12/2 mice. These results thus corroborate the
findings that the inflammatory response induced by anti-CD40-
treatment is dependent on both IL-12 and IL-23 [17], where the
response through the IL-12 receptor largely contributes to the
phenotype (Figure 6A). The severity of the weight loss correlates
with the serum cytokine levels of IFN-c and not of other cytokines
tested (Figure 6B). Together with the observation that NK cells
express the IL-12Rb2, these results suggest that, upon anti-CD40
treatment, NK cells contribute to the inflammatory response by
producing high levels of IFN-c in response to IL-12. In contrast,
although systemic inflammation was apparent in anti-CD40
antibody treated IL-23R2/2.Rag12/2 mice, we could not detect
IL-12 in the serum. This result suggests that signalling through IL-
23R somehow promotes IL-12 production. In mice expressing
both IL-12R and IL-23R, IL-12 production in response to IL-23
likely drives an amplification loop, enhancing the severity of the
systemic inflammatory response. As neither Lti-like nor NCR+
ILC3 cells have been reported to produce IL-12, additional
experiments are required to determine the source of IL-12
production in response to IL-23. Of interest, we also detected
serum levels of both IL-1b and IL-23 in IL-12Rb22/2.Rag12/2
mice, even in the absence of anti-CD40 treatment (Figure 6B).
Thus, in non-inflammatory conditions, signalling through IL-
12Rb2 negatively regulates systemic IL-1b production, one of the
mediators facilitating the differentiation of IL23R-expressing Th17
cells [28]. Moreover, IL-12 also negatively regulates the basal
levels of IL-23. Taken together, we demonstrate an intricate
interplay of both IL-12Rb2 expressing NK cells and IL-23R
expressing innate-lymphoid cells in a systemic inflammatory
setting.
Integration of IL-12Rb2 and IL-23R Pathways in Intestinal
Inflammatory Responses
In addition to the IL-12 and IL-23-dependent systemic
inflammatory response, anti-CD40 treatment in the Rag2/2
setting drives an IL-23-dependent inflammatory response in the
intestine [17]. As mentioned above, of all lymphoid tissues tested,
the proportion of IL23R+ lymphoid cells is highest in the gut-
associated lymphoid tissue (Figure 4A). In the Rag2/2 setting, IL-
23R expression is limited to innate lymphoid cells (Figure 3), which
have been mostly investigated in the context of intestinal
inflammatory responses. In this model, we can thus define the
role of IL-23R-expressing innate lymphoid cells in the context of
intestinal inflammation.
We performed histopathological examinations of intestinal
tissues of anti-CD40 treated Rag12/2 mice lacking either IL-
12Rb2 or IL-23R. Mice expressing IL-23R exhibit prominent
inflammation in the colon, characterized by a mixed infiltration in
the lamina propria, while no cellular infiltration is apparent in IL-
23R2/2.Rag12/2 mice (Figure 7A). Moreover, following treat-
ment with anti-CD40 antibody, there is a complete absence of
induction of mRNA for pro-inflammatory cytokines, namely Il1b,
Il6, Il12a, Il12b, Il17a, Il18, Il22 and Tnf in the proximal colon of
mice lacking IL-23R. Notably, there was not a complete lack of
response in IL-23R2/2.Rag12/2 mice, as both Ifng and Il10
mRNA were efficiently induced in the colon (Figure 7B). However,
this was insufficient to drive detectable histopathological lesions
(Figure 7A). Still, upon anti-CD40 treatment, IL-23R2/2.Rag12/
2 mice presented with a sizeable proportion of IL-23R+ cells in
the lamina propria of the small intestine and the colon, which was
mostly comprised on innate lymphoid cells (Figure 8A, B).
Remarkably, IL-23R expression was still not observed on dendritic
cells and macrophages in this experimental setting (Figure 8C).
In contrast to IL-23R2/2.Rag12/2 mice, IL-12Rb22/
2.Rag12/2 mice exhibited elevated mRNA levels of most pro-
inflammatory cytokines. Indeed, we surprisingly observed elevated
Ifng mRNA levels in the colon (Figure 7B), although we had not
detected IFN-c in the serum of these mice upon anti-CD40
treatment (Figure 6B). This result clearly indicates an IL-12-
independent pathway for local IFN-c production in intestinal
inflammation. As IL-18 has been shown to promote IFN-c
production, we investigated the regulation of Il18 mRNA
expression [29]. Upon anti-CD40 treatment, Il18 mRNA was
highest in IL-12Rb22/2.Rag12/2 mice relative to the other
strains, suggesting that IL-18 may promote IFN-c production in
this setting (Figure 7B). However, Il18 mRNA expression in anti-
CD40-treated IL-12Rb22/2.Rag12/2 mice was much lower than
at steady state levels, likely due to the destruction of epithelial cells,
which constitutively express Il18 mRNA [30] (Figure 7B). In
addition, Il18 mRNA levels were severely compromised in IL-
23R2/2.Rag12/2 mice, even in the non-inflammatory setting
(Figure 7B), suggesting that basal IL-23 response promotes the
constitutive expression of Il18 mRNA, adding to the already
complex regulation of Il18 mRNA levels [31]. Additional studies
are required to define whether IL-18 is truly responsible for the
enhanced IFN-c production in the IL-12Rb22/2.Rag12/2 mice
upon anti-CD40 treatment.
Finally, as IL-12Rb2 and IL-23R are respectively expressed by
NK cells and innate lymphoid cells in the Rag-deficient setting, we
chose to compare the relative proportion of these cell subsets in the
lamina propria of the small intestine of C57BL/6.Rag12/2, IL-
23R2/2.Rag12/2 and IL-12Rb22/2.Rag12/2 mice that had
received anti-CD40 treatment. We found that the proportion and
absolute number of NK cells did not vary between the three
strains, further suggesting that NK cells play little role in the local
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inflammatory response of the gut (Figure S4). In contrast, IL-
12Rb22/2.Rag12/2 mice presented with a significantly larger
proportion and number of innate lymphoid cells than both
C57BL/6.Rag12/2 and IL-23R2/2.Rag12/2 (Figure S4), pro-
viding further credence to the view that the IL-12 pathway
negatively regulates the IL-23-pathway. Moreover, this result
suggests that IL-12 may mediate its effect by modulating the
recruitment or accumulation of innate lymphoid cells to the
inflammatory site.
Taken together, these findings demonstrate that IL-23R-
expressing innate lymphoid cells play a key role in promoting
intestinal inflammation through the production of pro-inflamma-
tory cytokines, while IL-12Rb2-expressing cells negatively regulate
this process.
Discussion
The IL-23 and IL-12 pathways are intimately linked since these
cytokines share a protein subunit, IL-12p40, and their respective
receptors also share a common receptor chain, IL-12Rb1 [32].
The specific role of these cytokines has been elucidated, at least in
part, using IL-12p35, IL-12p40 and IL-23p19 deficient mice [33].
Yet, the expression profiles of IL-23 and IL-12 receptors have not
been extensively studied [34]. In particular, few studies have
directly addressed IL-12Rb2 subunit protein expression [35–37].
Recently, an IL-23R reporter mouse has allowed a more accurate
depiction of IL-23R expression on various cell subsets, although a
thorough characterization of IL-23R expression in different innate
immune cell types had not been performed [16]. Moreover, while
they share the IL-12Rb1 subunit for expression and function, IL-
12Rb2 and IL-23R co-expression has not been investigated. We
have thus decided to define the coordinated IL-12Rb2 and IL-
23R expression on immune cell subsets.
Using the IL-23ReGFP reporter mice, we have exhaustively
characterized the immune cell types expressing IL-23R. Unfortu-
nately, due to lack of a similar genetic tool and to the absence of
IL-12Rb2-specific antibody, the characterization of IL-12Rb2
expression remains limited to qPCR analysis of sorted cell subset.
Regardless, our data strongly support the view that the receptors
for IL-12 and IL-23 are not co-expressed; rather they are
expressed by distinct cell types in mice. This dichotomous pattern
of expression for IL-12 and IL-23 receptors will need to be
validated by flow cytometry on human cell subsets as the
appropriate antibodies become available. Regardless, the pattern
of receptor expression appears mostly conserved between human
and mouse. Of interest, human but not mouse CD8 T cells express
detectable levels of mRNA, suggesting that a greater proportion of
human CD8 T cells express the IL-23R relative to mouse CD8 T
cells. The reason for this discrepancy remains unclear but may be
of biological relevance when comparing IL-23-dependent inflam-
matory responses in both mouse and human. Still, the dichoto-
mous expression pattern of the receptors for IL-12 and IL-23, at
least in mice, suggests that the expression of both Il12rb2 and Il23r
are tightly regulated by distinct (and maybe opposing) transcrip-
tion factors. To that effect, we find that IL-12Rb2 expressing NK
cells exhibit a Th1-like signature, while IL-23R expressing cells
(which include Lti-like cells, T cell subset as well as a low number
of B cells) exhibit a Th17-like profile, suggesting that transcription
factors driving IL-12Rb2 and IL-23R maybe key regulators of
Th1 and Th17 signatures, respectively. In addition, RORct2/2
mice lack IL-23R expressing cd T CD27- cells. Interestingly, Rorc
appears to be essential in driving the differentiation of Lti cells
[38]. Still, it remains to be seen whether Rorc is required for the
expression of IL23R or whether it acts upstream in the
differentiation of IL-23R+ cells. Similarly, the specific transcription
factor(s) driving IL-12Rb2 expression has yet to be identified.
Notably, we could not detect IL-23ReGFP expression in NK
cells. Yet, in contrast with our findings, NK cells, characterized as
NK1.1+CD32 cells, were shown to modestly produce IL-22, but
not IL-17, when cultured in the presence of IL-23 [39]. One
possible explanation that may help reconcile these two findings, is
that the NK1.1+CD32 cells may include a subset of ILC3 cells that
are responsive to IL-23 [40,41]. This issue will likely be resolved as
more tools become available to study IL-12Rb2 expression. To
that effect, the commercially available antibodies apparently
directed to IL-12Rb2 exhibit non-specific staining in IL-12Rb2-
deficient mice. However, they have been used even in recent
publications to seemingly define IL-12Rb2 expression on various
cellular subsets [42–46]. Similarly, we demonstrate that IL-23R is
not expressed on dendritic cells, although a previous report using
an IL-23-Fc fusion protein suggested otherwise [26]. We would
like to caution investigators using these and other reagents, for
which a thorough validation has not been performed.
The contribution of IL-23R to inflammatory bowel diseases has
been explored in various mouse models of colitis, sometimes
demonstrating a protective role [47] and other times exacerbating
disease [48,49]. Our data strongly supports a pathogenic role for
IL-23R+ innate lymphoid cells specifically in the local innate
immune response [39,48,50]. This is in line with previous work
showing that both anti-CD90 (Thy-1) depletion in Rag1-deficient
mice or use of Rag1.Rorc-double deficient mice, which principally
lack IL-23R+ innate lymphoid cells, are similarly resistant to anti-
CD40-induced colitis [48]. Of note, although anti-CD90 antibod-
ies have now been used in various experimental settings to deplete
innate lymphoid cells [47,48,51], CD90 expression is also found
on a sizeable proportion of NK cells (Figure S5). Interestingly, a
protective role for innate lymphoid cells has mostly been observed
in the context of anti-CD90 depletion, suggesting that the CD90-
expressing NK cells may confer at least part of this protective role,
whereas IL-23R+ innate lymphoid cells participate more actively
in the local inflammatory responses.
Importantly, genome wide association studies in human
inflammatory bowel disease also suggest a prominent role of the
innate immune system and of IL-23R variants in defining
susceptibility to disease [6,52–56]. Our results are in agreement
with the view that innate immune cells expressing IL-23R
contribute to the pathology by producing pro-inflammatory
cytokines [50,57]. Specific targeting of IL-23 response in innate
immune cells in the gut may thus provide a therapeutic benefit to
patients suffering from inflammatory bowel disease.
In contrast, targeting IL-12R may be most relevant for the
control of systemic inflammatory responses and, by its negative
regulatory role on IL-23 responses, may actually exacerbate the
local inflammatory responses. In fact, IL-12Rb22/2 mice
eventually develop systemic autoimmune responses, characterized
by the presence of anti-nuclear autoantibodies [58]. Moreover,
these mice exhibit an increased propensity to develop cancers [58].
As Il12rb2 mRNA is abundantly expressed in NK cells, it is
tempting to suggest that lack of IL-12Rb2 expression is sufficient
to deregulate NK cell immune surveillance, thereby increasing
cancer prevalence.
The complexity of these two pathways, namely IL-12 and IL-
23, is further highlighted in the anti-CD40 inflammatory model.
Indeed, we intriguingly find detectable IL-12 serum levels only
when IL-23R is expressed. This suggests that the response to IL-23
promotes IL-12 production, highlighting an intricate interplay
between the two cytokines in promoting an inflammatory
response. In contrast, we detected basal serum levels of IL-1 and
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IL-23 in IL-12Rb2-deficient mice, even in steady state conditions.
This result suggests that the continuous response to IL-12 in non-
inflammatory conditions inhibits IL-1 production, known to drive
IL-23 responses. As such, at steady state, IL-12 may serve to
control inflammation.
In conclusion, our data reveal a dichotomous expression of the
IL-12Rb2 and IL-23R which help to explain the contribution of
the IL-12 and IL-23 pathways to distinct immune pathologies. In
addition, the lack of IL-12 and IL-23 receptor co-expression on a
given cell strongly suggests that IL-12 and IL-23 cytokines are not
involved in modulating the nature of the immune response by
changing the transcription profile of the responding cell. Instead,
and similar to what has been described in the context of Th1 and
Th17 [59], IL-12 and IL-23 cytokines may specifically maintain
the survival or enhance cytokine production of cells already
expressing their respective receptor and the corresponding
transcription profile. Our work also highlights an intricate
interplay of these two pathways in the cellular immune response
in the context of both a systemic and local inflammatory setting. A
better understanding of the dynamic regulation of IL-12Rb2 and
IL-23R in various inflammatory contexts is warranted to guide the
design of novel and specific therapeutic approaches in inflamma-
tory diseases.
Supporting Information
Figure S1 Commercially available antibodies to IL-
12Rb2 provide non-specific staining. (A) Representative
profile of APC-conjugated anti-IL-12Rb2 antibody (clone 305719
from R&D Systems) staining in total spleen cells from IL23R-
eGFP+/2 mice (control, left panel) and IL-12Rb22/2 mice
(right panel). Similar results were obtained with both the PE and
APC conjugated antibodies. (B) Representative profile of Pacific
Blue conjugated anti-CD49b antibody (clone DX5 from Biole-
gend), unconjugated anti-IL12Rb2 antibody (clone HAM10B9
from BD Biosciences) followed by PE-conjugated anti-hamster
IgG (clones G70-204, G94-90.5 from BD Biosciences) in total
spleen cells from IL23R-eGFP+/2 mice (control, left panel) and
IL-12Rb22/2 mice (right panel).
(TIF)
Figure S2 NK cells, dendritic cells, macrophages and
granulocytes do not express IL-23R. (A) A representative
plot presenting the percentage of IL23R-eGFP+ cells in the spleen.
(B) The expression of NK1.1, NKp46, CD49b, CD11c, CD11b,
mouse pDC antigen-1 (mPDCA-1), CD8a, and Gr1 on IL23R-
eGFP positive cells from the spleen of IL23R-eGFP+/2 mice is
shown. (C) Gating strategy for the extracellular staining of total
spleen cells which was applied in B. (D) Percentage of IL23R-
eGFP positive cells among B cells, CD4+ T cells, CD8+ T cells,
CD3+ CD4- CD8- TCR cd- T cells, cd T cells, Lti-like cells, and
NCR+ ILC3 cells in the spleen of IL23R-eGFP+/2 mice. Each
symbol represents data from one mouse. The horizontal bar
represents the mean of each group.
(TIF)
Figure S3 IL-23R-eGFP+ cd T cells are CD27-. Flow
cytometry profiles of cd T cell subsets based on CD27 and IL-
23R-eGFP expression is shown for the spleen, the lamina propria
of the small intestine (SI LP) and the lamina propria of the colon
(Colon LP). n $ 2.
(TIF)
Figure S4 Relative distribution of NK cells and innate
immune cells. The proportion and absolute number of NK cells
and innate immune cells from the lamina propria of the small
intestine of day 2 anti-CD40-treated C57BL/6.Rag12/2, IL-
23R-eGFP2/2.Rag12/2, IL-12Rb22/2.Rag12/2 mice, is
shown. Note the increased number of innate immune cells in IL-
12Rb22/2.Rag12/2 mice. The data represents the mean value
of two to three mice per group performed in three independent
experiments.
(TIF)
Figure S5 A subset of NK cells expresses the CD90 (Thy-
1) antigen. CD90 expression is shown on NK cells (CD49b+) of
(A) the lamina propria of the small intestine (SI LP) and the lamina
propria of the colon (Colon LP) for IL-23R-eGFP+/2 mice and
(B) the spleen, the lamina propria of the small intestine (SI LP) and
the lamina propria of the colon (Colon LP) for C57BL/
6.Rag12/2 mice. The intestines of C57BL/6.Rag12/2 mice
treated with anti-CD40 were processed at day 2. n= 2.
(TIF)
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